nebivololo awp
a.w.p. s.r.l. - nebivololo - nebivololo
nebivololo doc
doc generici srl - nebivololo - nebivololo
nebivololo abc
pharmacare s.r.l. - nebivololo - nebivololo
nebivololo e idroclorotiazide eg
eg s.p.a. - nebivolol and thiazides - nebivolol and thiazides
nebivolol-mepha 5 compresse
mepha pharma ag - nebivololum - compresse - nebivololum 5 mg nebivololi hydrochloridum di 5,45 mg, silice colloidalis anhydrica, magnesio stearas, carmellosum natricum, macrogolum 6000, lactosum monohydricum 192.4 mg, per compresso corrisp. sodio 0,06 mg. - beta-dei recettori adrenergici - synthetika
nebivololo actavis
general pharma solutions spa - nebivololo - nebivololo
nebivololo e idroclorotiazide mylan
mylan s.p.a. - nebivolol and thiazides - nebivolol and thiazides
nebivololo e idroclorotiazide teva italia
teva b.v. - nebivolol and thiazides - nebivolol and thiazides
nebivololo krka
krka d.d. novo mesto - nebivololo - nebivololo
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenti antineoplastici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.